Welcome to our dedicated page for Olaplex Holdings SEC filings (Ticker: OLPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olaplex Holdings, Inc. filings document the formal disclosures of a Nasdaq-listed beauty company with common stock registered under the symbol OLPX. Recent Form 8-K reports cover results of operations and financial condition, including sales performance across professional, specialty retail, and direct-to-consumer channels and U.S. and international markets.
The filing record also documents material definitive agreements, capital-structure disclosures, shareholder voting matters, governance changes, and compensatory arrangements. Company-specific disclosures include the completed acquisition of Purvala Bioscience by an Olaplex subsidiary, board composition updates, and other material-event reporting tied to the company’s hair-care innovation and public-company obligations.
Olaplex Holdings director Deirdre Findlay was granted 110,294 restricted stock units (RSUs) under the company's 2021 Equity Incentive Plan, reported on Form 4. Each RSU represents the conditional right to one share of common stock and was recorded as an acquisition on 08/12/2025 at no cash price. The RSUs will vest in full on the date of Olaplex's 2026 Annual Meeting of Stockholders, contingent on the reporting person's continued service through the vesting date. The filing was signed by an attorney-in-fact on 08/14/2025 and includes a Power of Attorney exhibit.
Olaplex Holdings director Pamela J. Edwards received a grant of 110,294 restricted stock units (RSUs) on 08/12/2025. Each RSU represents the conditional right to one share of Olaplex common stock and was reported as issued at a $0 price. The RSUs are scheduled to vest in full on the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to Ms. Edwards' continued service through that vesting date. Following the reported transaction, the reporting person beneficially owns 110,294 shares directly. The form was submitted via attorney-in-fact signature on 08/14/2025.
John P. Bilbrey, a director of Olaplex Holdings, Inc. (OLPX), received a grant of 294,118 restricted stock units (RSUs) on 08/12/2025. Each RSU converts into one share of common stock and the grant was recorded as an acquisition at $0 per RSU. After the grant, Mr. Bilbrey beneficially owns 640,021 shares in total, of which 318,418 shares are held indirectly through the Amended and Restated John P. Bilbrey Revocable Declaration of Trust. The RSUs vest in full on the date of Olaplex's 2026 Annual Meeting of Stockholders, conditional on his continued service through that date. The Form 4 was signed by an attorney-in-fact on 08/14/2025.
Olaplex Holdings, Inc. (OLPX) filed a Form 144 reporting a proposed sale of 108,335 common shares through Morgan Stanley Smith Barney LLC, scheduled approximately 08/14/2025 on NASDAQ. The filing states these shares were acquired as restricted stock units on 08/13/2025 and were paid as compensation; the aggregate market value is $158,167.16 and the issuer’s shares outstanding are listed as 667,081,086, so the sale represents about 0.016% of outstanding stock. No securities were reported sold by the filer in the past three months. The filer affirms they are not aware of any undisclosed material adverse information.
Olaplex (NASDAQ: OLPX) filed a routine Form 4 on June 29, 2025. The filing states that former director Paula Zusi ceased serving on the board effective June 10, 2025 and is therefore no longer subject to Section 16 reporting requirements. No purchases, sales, or other equity transactions were disclosed, and the tables for both non-derivative and derivative securities list no entries. The document is filed voluntarily to formally register Ms. Zusi’s change in reporting status.
Because the Form 4 reports no share transactions or monetary amounts, it represents an administrative update rather than a market-moving event.